Literature DB >> 27780567

Impacts of High-Protein Oral Nutritional Supplements Among Malnourished Men and Women with Sarcopenia: A Multicenter, Randomized, Double-Blinded, Controlled Trial.

Joel T Cramer1, Alfonso J Cruz-Jentoft2, Francesco Landi3, Mary Hickson4, Mauro Zamboni5, Suzette L Pereira6, Deborah S Hustead6, Vikkie A Mustad6.   

Abstract

BACKGROUND: Recent evidence suggests that nutritional interventions may improve muscle outcomes in malnutrition and sarcopenia.
OBJECTIVES: We evaluated the effects of 2 high-quality oral nutritional supplements (ONS) differing in amount and type of key nutrients in older adult men and women.
DESIGN: A multicenter, randomized, double-blinded, controlled clinical trial. PARTICIPANTS: Malnourished and sarcopenic men and women, 65 years and older (n = 330). INTERVENTION: A 24-week intervention period with 2 energy-rich (330 kcal) ONS treatment groups: Control ONS (CONS, 14 g protein; 147 IU vitamin D3) versus Experimental ONS (EONS, 20 g protein; 499 IU vitamin D3; 1.5 g CaHMB) taken twice daily. Both ONS also contained other vitamins, minerals, and nutrients in varying amounts. MEASUREMENTS: Isokinetic peak torque (PT, Nm) leg strength, grip strength (kg), and gait speed (m·s-1) were assessed at baseline and 12 and 24 weeks. Left and right leg muscle mass (LMM, kg) were assessed by dual-energy x-ray absorptiometry (DXA). Muscle quality (MQ) was leg strength expressed relative to the tested LMM (Nm·kg-1). Subgroup analyses were performed: severe sarcopenia (low skeletal mass index, low grip strength [<30 kg men; <20 kg women], low gait speed [<0.8 m·s-1]) and mild-moderate sarcopenia (low skeletal mass index, normal gait speed, or normal grip strength).
RESULTS: Both ONS groups (EONS and CONS) improved PT, MQ, grip strength, and gait speed from baseline with no treatment differences. Those with severe sarcopenia (44%) exhibited lower baseline PT and MQ, with no differences in strength improvements between treatments. However, participants with mild-moderate sarcopenia exhibited higher baseline PT and MQ, with differences in strength improvements at 12 weeks (EONS > CONS, P = .032) in those with normal grip strength. There were no treatment differences based on sarcopenic severity for either grip strength or gait speed.
CONCLUSION: ONS improved strength outcomes in malnourished older adults with sarcopenia. In those with mild-moderate sarcopenia, but not severe sarcopenia, consumption of the EONS improved leg muscle strength and quality compared with the standard CONS.
Copyright © 2016 AMDA – The Society for Post-Acute and Long-Term Care Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Elderly; enteral nutrition; gait speed; handgrip strength; isokinetic strength; medical nutrition therapy; muscle; nutrition-only intervention; performance

Mesh:

Substances:

Year:  2016        PMID: 27780567     DOI: 10.1016/j.jamda.2016.08.009

Source DB:  PubMed          Journal:  J Am Med Dir Assoc        ISSN: 1525-8610            Impact factor:   4.669


  34 in total

Review 1.  The Potential of β-Hydroxy-β-Methylbutyrate as a New Strategy for the Management of Sarcopenia and Sarcopenic Obesity.

Authors:  Andrea P Rossi; Alessia D'Introno; Sofia Rubele; Cesare Caliari; Stefano Gattazzo; Elena Zoico; Gloria Mazzali; Francesco Fantin; Mauro Zamboni
Journal:  Drugs Aging       Date:  2017-11       Impact factor: 3.923

Review 2.  Is β-hydroxy β-methylbutyrate an effective anabolic agent to improve outcome in older diseased populations?

Authors:  Mariëlle P K J Engelen; Nicolaas E P Deutz
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2018-05       Impact factor: 4.294

3.  Effect of Protein Supplementation Combined with Resistance Training on Muscle Mass, Strength and Function in the Elderly: A Systematic Review and Meta-Analysis.

Authors:  L Hou; Y Lei; X Li; C Huo; X Jia; J Yang; R Xu; X Wang
Journal:  J Nutr Health Aging       Date:  2019       Impact factor: 4.075

4.  International Clinical Practice Guidelines for Sarcopenia (ICFSR): Screening, Diagnosis and Management.

Authors:  E Dent; J E Morley; A J Cruz-Jentoft; H Arai; S B Kritchevsky; J Guralnik; J M Bauer; M Pahor; B C Clark; M Cesari; J Ruiz; C C Sieber; M Aubertin-Leheudre; D L Waters; R Visvanathan; F Landi; D T Villareal; R Fielding; C W Won; O Theou; F C Martin; B Dong; J Woo; L Flicker; L Ferrucci; R A Merchant; L Cao; T Cederholm; S M L Ribeiro; L Rodríguez-Mañas; S D Anker; J Lundy; L M Gutiérrez Robledo; I Bautmans; I Aprahamian; J M G A Schols; M Izquierdo; B Vellas
Journal:  J Nutr Health Aging       Date:  2018       Impact factor: 4.075

Review 5.  Sarcopenia: A Rheumatic Disease?

Authors:  Sarthak Gupta; Robinder J S Dhillon; Sarfaraz Hasni
Journal:  Rheum Dis Clin North Am       Date:  2018-06-12       Impact factor: 2.670

6.  The Combination of Preoperative Skeletal Muscle Quantity and Quality is an Important Indicator of Survival in Elderly Patients Undergoing Curative Gastrectomy for Gastric Cancer.

Authors:  Jun Watanabe; Tomihiro Osaki; Tadamasa Ueyama; Makoto Koyama; Masaru Iki; Kanenori Endo; Shigeru Tatebe; Yasuaki Hirooka
Journal:  World J Surg       Date:  2021-07-07       Impact factor: 3.352

7.  Sarcopenia in Liver Transplantation.

Authors:  John Montgomery; Michael Englesbe
Journal:  Curr Transplant Rep       Date:  2019-01-21

8.  Association of decreased muscle mass with reduced bone mineral density in patients with Graves' disease.

Authors:  Yongze Zhang; Yuzhen Ke; Lingning Huang; Ximei Shen; Sunjie Yan; Fengying Zhao; Yimei Li; Yuxi Lin
Journal:  Endocrine       Date:  2022-01-22       Impact factor: 3.633

9.  The incidence of sarcopenia among hospitalized older patients: results from the Glisten study.

Authors:  Anna Maria Martone; Lara Bianchi; Pasquale Abete; Giuseppe Bellelli; Mario Bo; Antonio Cherubini; Francesco Corica; Mauro Di Bari; Marcello Maggio; Giovanna Maria Manca; Emanuele Marzetti; Maria Rosaria Rizzo; Andrea Rossi; Stefano Volpato; Francesco Landi
Journal:  J Cachexia Sarcopenia Muscle       Date:  2017-09-14       Impact factor: 12.910

10.  Myopenia and precision (P4) medicine.

Authors:  John E Morley; Stefan D Anker
Journal:  J Cachexia Sarcopenia Muscle       Date:  2017-09-24       Impact factor: 12.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.